Genetic Mechanisms in Human Hypertension Renin-angiotensin-aldosterone System (RAAS) Inhibition Study
Primary Purpose
Hypertension
Status
Withdrawn
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Lisinopril, Atenolol
Sponsored by

About this trial
This is an interventional treatment trial for Hypertension focused on measuring High blood pressure
Eligibility Criteria
Inclusion Criteria:
- Male and female hypertensive participants who were previously studied in SCOR program.
Exclusion Criteria:
- Diabetes
- Taking other medications beside thyroid or estrogen supplements.
Sites / Locations
- Brigham and Women's Hospital
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Lisinopril, Atenolol
Arm Description
Outcomes
Primary Outcome Measures
One type of blood pressure medication will better treat individuals with certain genetic backgrounds.
Secondary Outcome Measures
Full Information
NCT ID
NCT01009944
First Posted
November 6, 2009
Last Updated
April 7, 2021
Sponsor
Brigham and Women's Hospital
Collaborators
University of Utah
1. Study Identification
Unique Protocol Identification Number
NCT01009944
Brief Title
Genetic Mechanisms in Human Hypertension Renin-angiotensin-aldosterone System (RAAS) Inhibition Study
Official Title
Genetic Mechanisms in Human Hypertension RAAS Inhibition Study
Study Type
Interventional
2. Study Status
Record Verification Date
April 2021
Overall Recruitment Status
Withdrawn
Why Stopped
Not funded.
Study Start Date
January 2007 (Actual)
Primary Completion Date
March 19, 2019 (Actual)
Study Completion Date
March 19, 2019 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Brigham and Women's Hospital
Collaborators
University of Utah
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this study is to develop an approach to provide personalized medicine to individuals who have hypertension (high blood pressure). The investigators plan to use people's genetic characteristics (traits) to determine what medication they should use to lower their blood pressure most effectively. The investigators will give individuals one of two medications to treat hypertension (lisinopril or atenolol). The investigators believe that depending on the individuals genetic background one medication will work better in lowering their blood pressure.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
Keywords
High blood pressure
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Lisinopril, Atenolol
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
Lisinopril, Atenolol
Other Intervention Name(s)
Tenormin (Atenolol), Prinivil, Zestril (Lisinopril)
Intervention Description
once a day for 14 weeks
Primary Outcome Measure Information:
Title
One type of blood pressure medication will better treat individuals with certain genetic backgrounds.
Time Frame
16 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Male and female hypertensive participants who were previously studied in SCOR program.
Exclusion Criteria:
Diabetes
Taking other medications beside thyroid or estrogen supplements.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Gordon H. Williams, MD
Organizational Affiliation
Brigham and Women's Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Brigham and Women's Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02115
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Genetic Mechanisms in Human Hypertension Renin-angiotensin-aldosterone System (RAAS) Inhibition Study
We'll reach out to this number within 24 hrs